Get 7 days FREE access to ALL funding rounds in real-time
Start your free trial now - no credit card required. Get real-time alerts, AI-matched leads, and our proprietary scoring system.
✓ 7-day free trial with FULL access • ✓ Real-time Chrome & Slack alerts • ✓ Companies & Industries dashboard
Your 7-day trial includes:
✓ FULL Starter features
✓ Real-time data & alerts
✓ 10 AI-matched leads daily
No credit card • Full access • Cancel anytime
EQT Life Sciences has led an $80 million Series A funding round in Mosanna Therapeutics, aiming to advance their nasal spray for sleep apnea treatment through Phase 2 Clinical Trials.
Amount Raised
$80 Million
Investors
Description
Mosanna Therapeutics raises $80 million in a Series A funding round to develop its nasal spray therapy for obstructive sleep apnea. The financing was led by EQT Life Sciences and Pivotal bioVenture Partners, with contributions from several co-lead investors. David Weber has been appointed as CEO to steer the company through clinical development. The company is based in Basel, Switzerland.